“We’re looking at containing systems and moving away from clean rooms. Right now, nothing is integrated or works together," said Robinson.
“There is talk of having small fixed-format manufacturing facilities – smaller but with a larger variety of materials.”
These would be cheaper and would suit manufacture of biologics in small volumes – for instance personalised medicines.
Further into the future, Robinson said the industry “aspired” to “smaller-scale agile manufacturing facilities,” some of which could be located inside healthcare sites, such as personalised cancer vaccines manufactured and administered in an oncology centre.